Cervical cancer (CC) is one of the most prevalent cancers worldwide. Single nucleotide polymorphisms (SNPs) of the epidermal growth factor receptor (EGFR) and epidermal growth factor (EGF) genes are associated with cancers in diverse populations; However, the roles of these...
Lung cancer is the leading cause of cancer deaths worldwide and remains one of the most difficult to cure. Tyrosine kinase receptors, such as the epidermal growth factor receptor (EGFR), are often aberrantly activated by gene mutation and drive tumor...
AbstractIntroduction Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is a standard first-line (1L) treatment for advanced/metastatic EGFR non-small cell lung cancer (NSCLC). Despite improved overall survival (OS) and progression-free survival (PFS) compared to earlier generation TKIs, resistance and disease progression...
Abstract In this study, molecular hybridization strategy was applied to design, synthesize a new series of quinazoline-4-one derivatives (E1–E8) as potential EGFR-targeting anticancer agents. The synthetic approach involved nucleophilic substitution reactions yielding high-purity compounds, characterized using FT-IR, 1H-NMR, and 13C-NMR...
ObjectiveThe optimal timing for combining brain radiotherapy with first-line third-generation EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mu 1 Introduction Lung cancer remains the leading cause of cancer-related mortality globally, with non-small cell lung cancer (NSCLC) representing the predominant...
SEOUL, South Korea, Feb. 12, 2026 /PRNewswire/ -- J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading oncology journal published by the...
SEOUL, South Korea, Feb. 12, 2026 /PRNewswire/ -- J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading oncology journal published by the...
A new study supports the use of kidney-protective medication for patients with type 1 diabetes Levels of kidney function alone had no apparent impact on the risk for diabetic ketoacidosis (DKA) among adults with type 1 diabetes (T1D), regardless of...
The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination...
